vs
Antero Midstream Corp（AM）とEmbecta Corp.（EMBC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Antero Midstream Corpの直近四半期売上が大きい（$291.1M vs $261.2M、Embecta Corp.の約1.1倍）。Antero Midstream Corpの純利益率が高く（41.5% vs 16.9%、差は24.6%）。Embecta Corp.の前年同期比売上増加率が高い（-0.3% vs -7.3%）。Antero Midstream Corpの直近四半期フリーキャッシュフローが多い（$186.9M vs $16.6M）。過去8四半期でAntero Midstream Corpの売上複合成長率が高い（3.9% vs -4.6%）
Antero Midstream Corpは米国のエネルギー企業で、デラウェア州に法人登録され、本社をコロラド州デンバーに置く。同社の石油・天然ガス埋蔵量は全てアパラチア盆地にあり、水圧破砕技術を用いて採掘を行っている。
Embecta Corp.は糖尿病ケアソリューションを専門とするグローバル医療テクノロジー企業です。インスリンペンニードル、注射器、輸液セット部品などを開発・製造・販売し、北米、欧州、アジア太平洋地域の患者、医療従事者、製薬企業にサービスを提供しています。
AM vs EMBC — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $291.1M | $261.2M |
| 純利益 | $120.7M | $44.1M |
| 粗利率 | — | 61.9% |
| 営業利益率 | 60.9% | 31.9% |
| 純利益率 | 41.5% | 16.9% |
| 売上前年比 | -7.3% | -0.3% |
| 純利益前年比 | 2.1% | — |
| EPS（希薄化後） | $0.25 | $0.74 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $261.2M | ||
| Q3 25 | $294.8M | $264.0M | ||
| Q2 25 | $305.5M | $295.5M | ||
| Q1 25 | $291.1M | $259.0M | ||
| Q4 24 | $287.5M | $261.9M | ||
| Q3 24 | $269.9M | $286.1M | ||
| Q2 24 | $269.8M | $272.5M |
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $44.1M | ||
| Q3 25 | $116.0M | $26.4M | ||
| Q2 25 | $124.5M | $45.5M | ||
| Q1 25 | $120.7M | $23.5M | ||
| Q4 24 | $111.2M | $0 | ||
| Q3 24 | $99.7M | $14.6M | ||
| Q2 24 | $86.0M | $14.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 61.9% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 66.7% | ||
| Q1 25 | — | 63.4% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 69.8% |
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 31.9% | ||
| Q3 25 | 61.2% | 21.4% | ||
| Q2 25 | 61.0% | 31.8% | ||
| Q1 25 | 60.9% | 24.3% | ||
| Q4 24 | 61.8% | 11.0% | ||
| Q3 24 | 60.2% | 9.2% | ||
| Q2 24 | 56.6% | 20.5% |
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | 16.9% | ||
| Q3 25 | 39.3% | 10.0% | ||
| Q2 25 | 40.8% | 15.4% | ||
| Q1 25 | 41.5% | 9.1% | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 37.0% | 5.1% | ||
| Q2 24 | 31.9% | 5.4% |
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $0.74 | ||
| Q3 25 | $0.24 | $0.44 | ||
| Q2 25 | $0.26 | $0.78 | ||
| Q1 25 | $0.25 | $0.40 | ||
| Q4 24 | $0.23 | $0.00 | ||
| Q3 24 | $0.21 | $0.24 | ||
| Q2 24 | $0.18 | $0.25 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.4M | $201.3M |
| 総負債低いほど良い | $3.2B | — |
| 株主資本純資産 | $2.0B | $-613.1M |
| 総資産 | $5.9B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 1.63× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | $201.3M | ||
| Q3 25 | — | $225.5M | ||
| Q2 25 | — | $230.6M | ||
| Q1 25 | — | $209.3M | ||
| Q4 24 | — | $210.0M | ||
| Q3 24 | — | $267.5M | ||
| Q2 24 | — | $275.1M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.2B | $1.6B | ||
| Q2 24 | $3.2B | — |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $-613.1M | ||
| Q3 25 | $2.1B | $-650.6M | ||
| Q2 25 | $2.1B | $-669.6M | ||
| Q1 25 | $2.1B | $-736.2M | ||
| Q4 24 | $2.1B | $-768.8M | ||
| Q3 24 | $2.1B | $-738.3M | ||
| Q2 24 | $2.1B | $-763.7M |
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $1.1B | ||
| Q3 25 | $5.7B | $1.1B | ||
| Q2 25 | $5.7B | $1.2B | ||
| Q1 25 | $5.8B | $1.1B | ||
| Q4 24 | $5.8B | $1.1B | ||
| Q3 24 | $5.8B | $1.3B | ||
| Q2 24 | $5.8B | $1.3B |
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.50× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $198.9M | $17.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $186.9M | $16.6M |
| FCFマージンFCF / 売上 | 64.2% | 6.4% |
| 設備投資強度設備投資 / 売上 | 11.1% | 0.2% |
| キャッシュ転換率営業CF / 純利益 | 1.65× | 0.39× |
| 直近12ヶ月FCF直近4四半期 | — | $205.8M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $17.2M | ||
| Q3 25 | $212.8M | $84.0M | ||
| Q2 25 | $265.2M | $81.2M | ||
| Q1 25 | $198.9M | $31.8M | ||
| Q4 24 | $232.7M | $-5.3M | ||
| Q3 24 | $184.9M | $26.6M | ||
| Q2 24 | $215.8M | $-2.1M |
| Q1 26 | $186.9M | — | ||
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $76.7M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $31.7M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | $184.3M | — | ||
| Q2 24 | $147.2M | $-11.8M |
| Q1 26 | 64.2% | — | ||
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | — | 27.3% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | -2.6% | ||
| Q3 24 | 68.3% | — | ||
| Q2 24 | 54.6% | -4.3% |
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 25.4% | 3.6% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | 0.39× | ||
| Q3 25 | 1.84× | 3.18× | ||
| Q2 25 | 2.13× | 1.78× | ||
| Q1 25 | 1.65× | 1.35× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | 1.82× | ||
| Q2 24 | 2.51× | -0.14× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
